Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Status:
Recruiting
Trial end date:
2024-09-21
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of isatuximab and to see how well it works in
treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis).
Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to
grow and spread.